Roche’s Alzheimer’s, breast cancer trials fail

Roche was ending a late-stage study of an experimental Alzheimer’s drug after it failed to prove effective, underlining the difficulty of treating the memory-robbing disease. The Swiss drugmaker also said a breast cancer trial had failed to demonstrate the benefit of adding its new drug Kadcyla to treatment programmes, damaging its hopes of broadening sales in an area it already dominates.